Cancer Research

Natural killer cells
#CAR-T #Natural killer cells #Oncology #Ovarian cancer #UCLA

Scientists develop CAR-NKT cell therapy for ovarian cancer

A new type of immunotherapy called CAR-NKT cell therapy has been shown to be more effective at fighting ovarian cancer than conventional CAR-T cell therapy.   Unlike current cellular immunotherapies that require patient-specific manufacturing and can cost hundreds of thousands of dollars, CAR-NKT cells can be produced… Read More

#Cancer Research #Editor's Choice #News

Pancreatic cancer
#Cancer vaccine #Colorectal cancer #Gene mutation #Oncology #Pancreatic cancer #UCLA

Off-the-shelf cancer vaccine shows promise in KRAS-driven cancers

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown encouraging early results in patients with pancreatic and colorectal cancer.  The study was led in part by investigators at the UCLA Health Jonsson Comprehensive Cancer Center and… Read More

#Cancer Research #Editor's Choice #News

CAR-T therapy for leukaemia
#CAR-T #Cell therapy #Haematology #In vivo #Lipid based nanoparticle (LNP) #NanoCell Therapeutics #Oncology

First non-viral DNA-based in vivo CAR-T generation

A new study has demonstrated the first stable, functional chimeric antigen receptor T-cells (CAR-T) cell generation in vivo using targeted lipid nanoparticles for DNA delivery.  The research evaluated NanoCell Therapeutics’ targeted lipid nanoparticle delivery system, termed NCtx, which enables the… Read More

#Cancer Research #News #Trending News

Monoclonal antibodies
#FDA #Haematology #Myeloma #Oncology #Orphan drugs #Sanofi

Sanofi’s antibody earns orphan status for multiple myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based Antibody-Dependent Cellular Cytotoxicity-enhanced (ADCC) monoclonal antibody (mAb).  The mAb targets G-protein coupled receptor family C group 5 member D (GPRC5D) for the potential treatment of patients with relapsed or refractory multiple… Read More

#Cancer Research #News #Regulatory

Diffuse large B-cell lymphoma
#Artificial intelligence (AI) #Lantern Pharma #Lymphoma #Oncology #Orphan drugs #Phase I trial

Complete response in heavily pre-treated lymphoma patient

A heavily pretreated patient with aggressive Grade 3 non-germinal centre diffuse large B-cell lymphoma (DLBCL) achieved a complete metabolic response in the ongoing Phase I clinical trial of Lantern Pharma’s LP-284.  Lantern uses an AI approach to determine mechanisms of action of any cancer focused molecule, identify… Read More

#Cancer Research #Editor's Choice #News

Colorectal cancer
#Cancer drug targets #Colorectal cancer #Oncology #University of Fukui

New molecular insights reveal potential colon cancer targets

New molecular insights into cancer stem cells have highlighted their potential as therapeutic targets.  In a recent study, researchers have revealed how transcription factors CDX1 and CDX2 suppress cancer cell stemness by blocking β-catenin’s ability to activate key genes like LGR5.   Their findings showed that… Read More

#Cancer Research #Editor's Choice #News

#Clinical trials #Next generation sequencing #Oncology #Sequencing

Bridging the clinical trials gap in cancer

Kathy Davy, President of Next-Generation Clinical Sequencing Division, Thermo Fisher Scientific, asks how clinical trials in cancer can be accelerated through the use of rapid next-generation sequencing (NGS) technology. Every cancer diagnosis marks the beginning of an urgent and often overwhelming journey for patients and their families. And in some… Read More

#Business & Investment #Cancer Research #Exclusive Content

#Dispatch Bio #Immunotherapy #Oncology #Solid tumours #Start-ups

Biotech aims to create universal solid tumour therapy

Dispatch Bio has officially launched with a stated mission to engineer a universal treatment across solid tumours.  Immunotherapies have struggled to effectively treat solid tumours due to the lack of a tumour-specific target and the presence of an immune-suppressive tumour microenvironment.   Dispatch’s Flare platform has… Read More

#Business & Investment #Cancer Research #News #Start-up Zone

#Cancer biology #Genetic diseases #Regenerative Medicine #Stem cells #Trogenix

Harnessing heterogeneity to treat cancer patients

Cancer is no longer seen as a simple disease of unchecked cell growth, but as a complex, adaptive ecosystem shaped by genetic mutations, immune evasion, and transcriptional plasticity that allow tumours to survive and evolve. Steve Pollard, CSO & Founder of Trogenix and Professor of Stem Cell and Cancer Biology,… Read More

#Cancer Research #Exclusive Content

Cancer cells
#Cancer research #Institute of Cancer Research #Skin cancer

SLC7A11 inhibitors could remove skin cancer’s protective armour

Scientists have uncovered a protein that acts like a ‘suit of armour’ for cancer cells, shielding them from hostile environments and allowing one of the deadliest forms of skin cancer to spread through the body. A team of researchers from The Institute of Cancer Research, London, has identified that a… Read More

#Cancer Research #News

FDA headquarters
#Cancer research #Drug discovery #FDA #Fujifilm #Regulatory

FUJIFILM’s biliary tract cancer drug granted FDA orphan status

FUJIFILM Pharmaceuticals’ FF-10832—an investigational liposomal formulation of gemcitabine—has granted orphan drug designation for the treatment of biliary tract cancer (BTC) by the US Food and Drug Administration (FDA). FF-10832 is currently being evaluated in Phase IIa studies as monotherapy or in combination with pembrolizumab for the treatment of solid tumours… Read More

#Cancer Research #News

#Cancer drug targets #Cancer research #European Union #Rare disease #Regulatory

EU go-ahead for nasopharyngeal carcinoma drug

The European Commission has approved Tevimbra (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. Nasopharyngeal carcinoma is a rare cancer in which malignant cells form in the nasopharynx, the upper… Read More

#Cancer Research #News #Regulatory

Trophy
#Awards #Cancer research #Cancer Research Horizons #Cancer Research UK

Cancer Research Horizons rewards innovation and entrepreneurship

Cancer Research Horizons, the innovation arm of Cancer Research UK, announced the winners of its third Innovation and Entrepreneurship Awards during an awards ceremony at Merchant Taylors’ Hall, London. Dr Alessia Errico, Associate Director of Search and Evaluation at Cancer Research Horizons, said: “These remarkable innovators demonstrate the determination and… Read More

#Cancer Research #News

Bladder
#AstraZeneca #Bladder cancer #European Commission #Monoclonal antibodies #Oncology

EU-approved bladder cancer therapy reduces death risk by 25%

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment.  According to the decision, this treatment should be followed by Imfinzi as monotherapy adjuvant treatment… Read More

#Cancer Research #News #Regulatory

Cancer cells
#Chemotherapy #Genetics / genomics #Oncology #University of Cambridge #Wellcome Sanger Institute

Chemotherapy finding could guide better treatments

For the first time, scientists have systematically studied the genetic effects of chemotherapy on healthy tissues.  Researchers from the Wellcome Sanger Institute, the University of Cambridge, Cambridge University Hospitals NHS Foundation Trust (CUH) and their collaborators analysed blood cell genomes from 23 patients of all ages who… Read More

#Cancer Research #News

Tumour microenvironment
#Cancer research #Drug discovery #Insilico Medicine #Solid tumours

First patient receives novel MAT2A inhibitor for solid tumours

The first patient has been dosed in a global multicentre clinical trial to evaluate ISM3412, a potentially best-in-class, MAT2A inhibitor with novel structure, in patients with locally advanced and metastatic solid tumours. The Phase I study consists of two parts: dose escalation and dose selection optimisation, where participants will receive… Read More

#Cancer Research #News